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Abstract
Myelin basic protein (MBP) is thought to be responsible for adhesion of the intracellular surfaces of compact myelin to
give the major dense line. The 17 and 21.5 kDa isoforms containing exon II have been reported by others to localize to the
cytoplasm and nucleus of murine oligodendrocytes and HeLa cells while the 14 and 18.5 kDa isoforms lacking exon II are
confined to the plasma membrane. However, we show that the exon II3 18.5 kDa form and a recombinant exon II 21.5 kDa
isoform both caused similar aggregation of acidic lipid vesicles, indicating that they should have similar abilities to bind to
the intracellular lipid surface of the plasma membrane and to cause adhesion of those surfaces to each other. The circular
dichroism spectra of the two isoforms indicated that both had a similar secondary structure. Thus, both isoforms should be
able to bind to and cause adhesion of the cytosolic surfaces of compact myelin. The fact that they do not could be due to
differences in post-translational modification in vivo, trafficking through the cell and/or subcellular location of synthesis, but
it is not due to differences in their lipid binding. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Myelin basic protein (MBP) is thought to be re-
sponsible for adhesion of the intracellular surfaces of
the compact multilayered myelin sheath. It is located
at the major dense line of myelin [1,2] and it causes
aggregation of lipid vesicles containing negatively
charged lipids [3^9]. In mice and rats, MBP occurs
as four major size isoforms of 21.5, 18.5, 17 and 14
kDa due to alternative splicing of a single primary
transcript of the MBP gene which contains seven
exons. All isoforms contain exons I, III, IV, V and
VII while only the 21.5 and 17 kDa forms contain
exon II. The 21.5 and 18.5 kDa forms also contain
exon VI. The exon II 21.5 and 17 kDa forms are
expressed at high levels early in myelination and in
immature oligodendrocytes in culture [10], while the
exon II3 14 and 18.5 kDa forms are the primary
forms expressed later in myelination, in mature oli-
godendrocytes and in adult myelin. In human, the
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18.5 kDa form is the primary form in adult myelin
but exon II forms are expressed during fetal devel-
opment and during remyelination [11].
Interestingly, these di¡erent isoforms localize to
di¡erent regions of the cell when expressed individu-
ally in transfected cells. Both in Shiverer mouse oli-
godendrocytes lacking endogenous MBP [12] or in
HeLa cells [13], the exon II forms were found dis-
tributed in the cytoplasm and in the nucleus but not
at the plasma membrane, while the exon II3 forms
were con¢ned to the plasma membrane. The exon
II forms were transported into the nucleus by active
transport [14]. Entry was directly related to the
growth rate of the cells, as found for bona ¢de nu-
clear proteins, and was suppressed by cell-cell con-
tact [15]. In wild-type mouse oligodendrocytes con-
taining endogenous MBP, a transfected tagged 14
kDa form was found in the cytoplasm and nucleus
in addition to being bound to the plasma membrane,
leading to the suggestion that the exon II forms
might help to transport exon II3 forms into the nu-
cleus [16].
The absence of the exon II forms at the plasma
membrane of cultured OLs and non-glial cells has led
to the suggestion that the presence of the exon II
domain suppresses membrane binding and that the
exon II forms do not participate in compaction of
myelin [15,17]. However, exon II forms are found
equally in compact myelin and in the radial compo-
nent (a junctional specialization within internodal
myelin), although the exon II3 forms are found
more preferentially in compact myelin compared to
the radial component [18]. Furthermore, like the rest
of the MBP sequence, the exon II domain is also
highly basic and would contribute an additional net
positive charge of four to the net positive charge of
20 for the 18.5 kDa form, giving a total net positive
charge of 24 for the 21.5 kDa form at neutral pH.
Thus, unless the presence of exon II causes a signi¢-
cant change in the conformation, degree of oligome-
rization or degree of post-translational modi¢cations
of MBP in vivo, it is expected to have little e¡ect on
electrostatic interactions of MBP with negatively
charged lipids at the cytosolic surface of the myelin
or oligodendrocyte membrane. The single Cys81 of
exon II has been found to cause some dimerization
of a recombinant 21.5 kDa form on gels but only of
a fraction of the protein [19].
MBP probably causes adhesion of the cytosolic
surfaces of myelin by binding to acidic lipids. The
only other membrane protein present in su⁄cient
quantity to bind a signi¢cant amount of MBP is
the transmembrane proteolipid protein (PLP). PLP
is also positively charged at the cytosolic surface
[20] and has been shown to bind only to the least
positively charged isomer of MBP in which six Arg
residues have been deiminated to citrulline [21]. Ag-
gregation of lipid vesicles containing negatively
charged lipids by MBP is a useful model system to
study factors which might a¡ect its ability to cause
adhesion of the intracellular surfaces of myelin. This
approach has been used to study the e¡ect of post-
translational charge modi¢cations to the 18.5 kDa
form on its ability to cause adhesion of lipid vesicles
[6,21,22]. It is not known whether MBP causes this
adhesion as a monomer or as a dimer but it can do
so quite e¡ectively in the absence of any other pro-
teins. In the present study, we compare the ability of
the recombinant 21.5 kDa form of human MBP [19]
and the 18.5 kDa form of bovine MBP, using the
least modi¢ed, most positively charged form of the
latter, C1, to aggregate lipid vesicles.
2. Materials and methods
2.1. Lipids and proteins
Bovine MBP was isolated from bovine brain white
matter according to the method of Cheifetz and
Moscarello [6]. It was separated into its charge iso-
mers C1^C5 by ion exchange chromatography at al-
kaline pH on CM52 as described [23,24]. C1, the
least modi¢ed component, was used. The recombi-
nant 21.5 kDa isoform of human MBP bearing a
C-terminal histidine tag was expressed in Escherichia
coli and puri¢ed as described [19]. Egg L-K-phospha-
tidylcholine (PC) was purchased from Sigma (St.
Louis, MO, USA) and bovine brain L-K-phospha-
tidylserine (PS) was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Lipids were chromato-
graphically pure and were used as supplied. [14C]di-
palmitoylphosphatidylcholine ([14C]DPPC), speci¢c
activity 110 mCi/mmol, was from Dupont NEN
(Boston, MA, USA).
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2.2. Preparation of large unilamellar vesicles (LUVs)
Chloroform solutions of the lipids were combined
in a PC/PS 4:1 mol ratio and the solvent evaporated
under a stream of nitrogen. The lipid was redissolved
in 1 ml benzene, frozen and lyophilized overnight.
The dry lipid ¢lm (42 Wmol) was hydrated in 1.5 ml
of 10 mM HEPES bu¡er containing 0.1 mM EDTA
at pH 7.4 and dispersed by vortex mixing. LUVs
were prepared by extrusion of the lipid suspension
through a 100 nm pore ¢lter using an Avestin Li-
posoFast extruder (Ottawa, Canada) as described
earlier [22,25].
2.3. Aggregation assay
Solutions of 21.5 and 18.5 kDa MBP were made in
distilled water at concentrations of 1.5, 0.75 and
0.5 mg/ml. The LUVs were diluted to a ¢nal concen-
tration of 0.6 Wmol lipid/ml in 10 mM HEPES bu¡er,
pH 7.4, containing 0.1 mM EDTA and varying NaCl
concentrations from 10 to 210 mM as described ear-
lier [9,22]. After addition of NaCl, the LUVs were
sonicated brie£y in a bath sonicator and left over-
night at 4‡C to allow for equilibration of the salt
concentration inside and outside the LUVs.
Although the cytosol of oligodendrocytes contains
more K than Na, in a previous study, we found
that both cations had similar e¡ects on MBP-induced
aggregation [9]. An aliquot (10 Wl) of the protein
solutions was added to 1 ml of diluted LUVs, giving
MBP to lipid weight ratios of 1:90, 1:60 and 1:30 in
Sarstedt acrylic cuvettes (Newton, NC, USA) as de-
scribed earlier [9]. The cuvette was gently inverted
three times to mix, left at room temperature for
10 min and aggregation was measured from the ab-
sorbance at 450 nm with a Hitachi U-2000 spectro-
photometer at room temperature. Absorbance of
protein-free LUVs at di¡erent Na concentrations
was also measured and subtracted from that of pro-
tein-containing LUVs to give vAbs. The absorbance
of protein-free LUVs was low (0.05) and addition of
210 mM NaCl increased it to only 0.07.
2.4. Binding assay
PC/PS 4:1 LUVs containing [14C]DPPC (7500
cpm/Wmol lipid) were prepared as described above
in 80 and 210 mM NaCl at a lipid concentration of
0.6 Wmol/ml. A small aliquot of protein solution con-
taining 75 Wg protein was added (initial weight%
protein of 3.4) and the lipid-protein vesicles were
sedimented by centrifugation at 95 000Ug in a Beck-
man Optima L-90K ultracentrifuge at 4‡C for 2 h.
The supernatant was removed and aliquots were tak-
en for counting [14C]DPPC and for protein analysis
by the Peterson assay [26]. Virtually all (99%) of the
lipid at 80 mM NaCl sedimented under these condi-
tions. The pellet was resuspended in 450 Wl bu¡er,
aliquots were taken for counting and protein assay
and the weight% protein bound to the lipid pellet
was determined as the ratio of protein weight to
the total weight of lipid plus protein multiplied by
100.
2.5. Circular dichroism (CD) spectroscopy
CD spectra of the two isoforms were measured at
190^250 nm on a Jasco J720A spectropolarimeter
using a 0.01 cm pathlength cell at ambient temper-
ature. Appropriate dilutions of solutions of the
two isoforms in deionized water were made with
10 mM phosphate bu¡er, pH 7.4, with or without
2 mg/ml sodium dodecyl sulfate (SDS). Protein
concentrations were in the range of 1 mg/ml and
were quantitated by amino acid analysis or the Pe-
terson assay [26]. CD spectra of the bu¡ers alone
were subtracted from the protein spectra. The CD
spectra are expressed as the mean residue ellipticity,
3 (degreeUcm2/dmol).
3. Results and discussion
The lipid composition of the cytosolic surface of
myelin is thought to contain about 15 mol% nega-
tively charged lipid, mostly PS with a small amount
of phosphatidylinositol [27]. The remainder consists
mainly of the electrostatically neutral zwitterionic
lipids PC, phosphatidylethanolamine and sphingo-
myelin. In order to resemble the lipid content of
the cytosolic surface of myelin, LUVs of PC contain-
ing 20 mol% PS were used for this study. The ability
of the two size isoforms of MBP to cause aggrega-
tion of PC/PS 4:1 (m/m) LUVs at di¡erent Na con-
centrations was compared at three lipid to protein
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weight ratios, 30:1, 60:1 and 90:1, higher than the
ratio in central nervous system compact myelin,
about 14:1 [28]. At these higher lipid to protein ra-
tios, the negatively charged lipid is in excess relative
to the number of positively charged residues of the
protein (21, 14 and 7 PS/net positive charge). Thus,
the protein cannot neutralize all of the charged lipid
and the vesicles have a net negative charge. At these
lipid to protein ratios, the vesicles repel each other
and the protein cannot aggregate them unless the
lipid charge is shielded by salt. The ability of the
protein to aggregate the vesicles is more dependent
on modi¢cations to the protein under these condi-
tions than at the low lipid to MBP ratio in compact
myelin, as shown previously for charge isoforms of
MBP [22].
Fig. 1 shows that the absorbance of the lipid-pro-
tein vesicles increases with an increasing Na concen-
tration up to about 160 mM Na for all three lipid
to protein ratios, indicating that aggregation in-
creases with an increasing salt concentration. Ab-
sorbance decreases at 210 mM Na. This has been
shown to be due to dissociation of some of the pro-
tein at higher salt concentrations, thus resulting in a
decreased aggregation [9]. Both the 21.5 and 18.5 kDa
forms of MBP show a similar dependence on the
Na concentration up to 160 mM Na. At 210 mM
Fig. 2. Dependence of absorbance on the protein concentration expressed as weight% of the total amount of lipid and protein in the
vesicles, for the 21.5 kDa isoform (R) and 18.5 kDa isoform (E) at 60 mM NaCl and for the 21.5 kDa isoform (O) and 18.5 kDa
isoform (F) at 210 mM NaCl.
Fig. 1. Dependence on the NaCl concentration of absorbance
of PC/PS 4:1 LUVs in the presence of 21.5 kDa isoform (b)
and 18.5 kDa isoform (E) at a lipid to protein weight ratio of
30:1; 21.5 kDa isoform (F) and 18.5 kDa isoform (O) at a lip-
id to protein weight ratio of 60:1; 21.5 kDa isoform (R) and
18.5 kDa isoform (a) at a lipid to protein weight ratio of 90:1.
An increase in absorbance is due to aggregation of the LUVs
by the protein. The decrease in absorbance at high salt concen-
trations is due to dissociation of the protein from the LUVs,
resulting in decreased aggregation. vAbs is the di¡erence in ab-
sorbance at 450 nm of protein-bound LUVs from protein-free
LUVs. The latter ranged from 0.05 to 0.07.
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Na, however, absorbance is less for the 18.5 kDa
form than the 21.5 kDa form, particularly at the
30:1 weight ratio, suggesting that the 18.5 kDa
form is dissociated more readily by salt than the
21.5 kDa form. This was con¢rmed by a binding
assay at 80 and 210 mM NaCl as shown in Table
1. The total intracellular monovalent cation concen-
tration of oligodendrocytes is 75^90 mM [9]. All of
the protein added to the lipid vesicles is bound at the
physiological intracellular salt concentration of
80 mM NaCl for both isoforms. However, at
210 mM NaCl, some of the protein dissociates due
to shielding of electrostatic interactions with the lip-
id. More of the 21.5 kDa form remains bound than
the 18.5 kDa form, indicating a tighter association of
the 21.5 kDa form due to its greater net positive
charge.
The dependence of aggregation on the protein con-
centration is shown in Fig. 2 at two di¡erent salt
concentrations. At 60 mM Na where aggregation
is not yet maximal, there is no di¡erence in the abil-
ity of the two size isoforms to cause aggregation of
the vesicles. At 210 mM Na, where protein dissoci-
ation has started, the 21.5 kDa form causes greater
aggregation than the 18.5 kDa form. Thus, the
21.5 kDa form of MBP binds to negatively charged
lipid bilayers as well as or better than the 18.5 kDa
form and causes similar aggregation of vesicles. The
high lipid to MBP ratio used for these studies should
magnify any di¡erences in their ability to bind to and
Fig. 3. Representative CD spectra of 21.5 kDa (curve 1) and 18.5 kDa (curve 2) isoforms in (A) 10 mM phosphate bu¡er, pH 7.4,
and (B) in the presence of 2 mg/ml SDS in the same bu¡er. The CD data are expressed as the mean residue ellipticity, 3
(degreeUcm2/dmol). Relative di¡erences and similarities of the spectra of the two isoforms were reproducible.
Table 1
E¡ect of the salt concentration on the amount of 18.5 and
21.5 kDa forms of MBP bound to lipida
Size isomer NaCl (mM) MBP bound (weight%)
18.5 kDa 80 3.4
21.5 kDa 80 3.4
18.5 kDa 210 1.7
21.5 kDa 210 2.5
a75 Wg protein was added to 2.15 mg lipid, PC/PS 4:1 LUVs
(3.4 weight% protein), and the weight% MBP bound to the lip-
id was determined as described in Section 2.
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aggregate lipid vesicles. Thus, at the low lipid to
MBP ratio in compact myelin and at physiological
monovalent salt concentrations, no di¡erence in the
ability of the two size isoforms to bind to and adhere
acidic lipid surfaces would be expected.
Although we compared bovine brain 18.5 kDa
MBP with recombinant human 21.5 kDa MBP, we
have never observed any di¡erence in the ability of
human and bovine MBP to aggregate vesicles
(Boggs, unpublished). There are only 16 residues
which di¡er in the sequences of human and bovine
18.5 kDa MBP and no di¡erence in net positive
charge [28]. However, the recombinant 21.5 kDa
form also has six His residues at the C-terminus.
These are expected to be unprotonated at pH 7.4.
If protonated, they may contribute to the ability of
the 21.5 kDa isoform to bind and aggregate vesicles.
If all the His residues in the proteins are protonated,
then, the 21.5 kDa His-tagged isoform would have a
net positive charge of 41 compared to 35 for the
native 21.5 kDa isoform and 31 for the 18.5 kDa
isoform. It is very unlikely that the extra six His
residues of the His-tagged protein would convert it
from a non-membrane-binding protein into a binding
one, particularly since the C-terminal end of the na-
tive form of both charge isomers is already positively
charged with two Arg residues at the C-terminus.
CD spectra of the two isoforms show that in aque-
ous solution, they both have a mostly random struc-
ture. The mean residue elipticity of the 21.5 kDa
form is reproducibly less negative (15% þ 3) at 198^
200 nm but similar at 215^240 nm to that of the
18.5 kDa form, indicating that the 21.5 kDa form
has a little more secondary structure in solution
than the smaller form (Fig. 3). The small di¡erence
in elipticity observed is unlikely to be due to the
di¡erence in puri¢cation procedures of the recombi-
nant and native forms since two quite di¡erent puri-
¢cation procedures were found to have no e¡ect on
the CD spectrum of MBP [29]. It is more likely due
to the His tag at the C-terminal than due to the
presence of exon II, since exon II of human MBP
contains ¢ve prolines in a segment of 26 amino acids,
which is not expected to result in an increased sec-
ondary structure. In the presence of the anionic de-
tergent SDS, the CD spectra are more similar for the
two isoforms. The elipticity greatly increases at wave-
lengths below 200 nm and decreases at wavelengths
above 205 nm, indicating that SDS induces a signi¢-
cant amount of secondary structure for both iso-
forms as reported previously for the 18.5 kDa form
[29^31]. The % di¡erence in elipticity for the two
isoforms in SDS is 10 þ 2. Thus, in the presence of
lipid, the two isoforms probably have a relatively
similar secondary structure.
These results indicate that the greater nuclear tar-
geting of the 21.5 kDa form of MBP and the greater
plasma membrane binding of the 18.5 kDa form in
mouse oligodendrocytes and in HeLa cells must be
due to some reason other than a di¡erence in the
ability of the unmodi¢ed forms of these size isoforms
to bind to and cause adhesion of membranes. A dif-
ference in secondary structure also is not likely to
account for these results. The studies of cellular lo-
calization of the 21.5 kDa isoform of MBP were
carried out using mouse MBP while our aggregation
studies utilized the 21.5 kDa form of human MBP.
The sequence of exon II in mouse MBP di¡ers from
human at four out of 26 residues, with Pro-67CGlu,
Gly-7CSer, Gln-18CArg and Asn-23CHis substi-
tutions occurring in mouse MBP [11]. These would
not a¡ect the net charge of the 21.5 kDa form at
neutral pH and thus would be unlikely to a¡ect the
ability of the mouse 21.5 kDa isoform to bind to and
aggregate acidic lipid vesicles.
Possibly some post-translational modi¢cations of
the exon II forms cause their targeting to the nu-
cleus, although phorbol ester inhibited it, suggesting
that phosphorylation of MBP may inhibit nuclear
targeting [14]. The extent of post-translational mod-
i¢cations of the exon II forms of MBP in oligoden-
drocytes or in non-glial cells where they have been
expressed is not known. Post-translational modi¢ca-
tions which decrease the net positive charge of MBP
decrease its ability to cause aggregation of acidic
lipid vesicles [6,21] and increase its susceptibility to
dissociation from the lipid at high salt concentrations
[22]. They may also a¡ect the secondary structure.
Phosphorylation increases the secondary structure
of the protein in solution [32], although the e¡ect
on the lipid-bound protein has not been determined.
Deamidation, however, has no e¡ect on the second-
ary structure [33]. Another possible cause of di¡erent
localization of the exon II isoforms is the presence
of a nuclear targeting sequence in exon II or un-
masking of a nuclear targeting sequence identi¢ed
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in exon I by the presence of exon II, as suggested by
Staugaitis et al. [17]. Alternatively, targeting may be
due to the localization of MBP synthesis. The
mRNAs for exon II3 forms of MBP are transported
far into oligodendrocyte processes while exon II
mRNAs have been detected only in the cell body
[34]. Thus, it may be the mRNA exon II sequence
which regulates sorting and tra⁄cking of MBP
rather than the MBP protein sequence.
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